Investing in pharmaceuticals is not without its risks

Investing in the stock market has long been compared to a high-stakes game of poker, where shareholders, putting their life savings on the line, strive for rewards in the form of capital growth or dividends. But beyond personal financial gain, investors play a critical role in funding medical research that has the potential to save millions of lives. A prime example lies in the fight against obesity, a condition linked to a myriad of severe health issues, including heart disease, stroke, and cancer.

Novo Nordisk, the Danish pharmaceutical giant, has been at the forefront of diabetes research for nearly a century, with its pioneering work in insulin production. Despite its strong market position, Novo Nordisk was historically considered too expensive for retail investors due to its low dividend yield and high taxation in Denmark. However, rumors of promising weight-loss drugs, Wegovy and Ozempic, spurred a re-evaluation of the stock.

Novo Nordisk, currently the most valuable company in Europe, owes much of its success to institutions like the NHS and Medicare recognizing the significant cost savings of treating obesity and related illnesses with these innovative medications. The market for weight-loss drugs is estimated to reach $100 billion by 2030, and Novo is well-positioned to benefit.

Similarly, Eli Lilly, a U.S.-based pharmaceutical giant, is making strides in this domain with its diabetes and weight-loss drugs, Mounjaro and Zepbound. The first-quarter results saw a 26% increase in revenues driven by the demand for its diabetes and weight-loss medications.

However, investing in pharmaceuticals is not without its risks. Take Pfizer, for instance, which initially benefited from its COVID-19 vaccine, causing a sharp spike in its share price in 2021, only to see it decline in the following years.

Investing in healthcare aligns with my desire to fund innovative treatments that have the potential to improve the quality of life for millions. Novo Nordisk and Eli Lilly are examples of companies whose work has made a significant difference in treating obesity and diabetes. Investing in them offers the opportunity to generate wealth while contributing to the greater good.

In conclusion, investing in the pharmaceutical industry offers the potential for substantial financial rewards while also contributing to advances in medical research. Despite the inherent risks, supporting companies like Novo Nordisk and Eli Lilly allows investors to do well by doing good, helping to fund innovations that have the power to transform lives.